Alphamab Oncology (FRA:3NK)

Germany flag Germany · Delayed Price · Currency is EUR
1.170
+0.040 (3.54%)
At close: Nov 27, 2025
137.80%
Market Cap1.12B
Revenue (ttm)93.42M
Net Income (ttm)27.67M
Shares Outn/a
EPS (ttm)0.03
PE Ratio40.42
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume65
Open1.170
Previous Close1.130
Day's Range1.170 - 1.170
52-Week Range0.354 - 1.680
Betan/a
RSI48.74
Earnings DateNov 28, 2025

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 420
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3NK
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.